Magnetic hyperthermia (MHT) is a therapeutic modality for the treatment of solid tumors that has now accumulated more than 30 years of experience. In the ongoing MHT clinical trials for the treatment of brain and prostate tumors, iron oxide nanoparticles are employed as intra-tumoral MHT agents under a patient-safe 100 kHz alternating magnetic field (AMF) applicator. Although iron oxide nanoparticles are currently approved by FDA for imaging purposes and for the treatment of anemia, magnetic nanoparticles (MNPs) designed for the efficient treatment of MHT must respond to specific physical–chemical properties in terms of magneto-energy conversion, heat dose production, surface chemistry and aggregation state. Accordingly, in the past few decades, these requirements have boosted the development of a new generation of MNPs specifically aimed for MHT. In this review, we present an overview on MNPs and their assemblies produced via different synthetic routes, focusing on which MNP features have allowed unprecedented heating efficiency levels to be achieved in MHT and highlighting nanoplatforms that prevent magnetic heat loss in the intracellular environment. Moreover, we review the advances on MNP-based nanoplatforms that embrace the concept of multimodal therapy, which aims to combine MHT with chemotherapy, radiotherapy, immunotherapy, photodynamic or phototherapy. Next, for a better control of the therapeutic temperature at the tumor, we focus on the studies that have optimized MNPs to maintain gold-standard MHT performance and are also tackling MNP imaging with the aim to quantitatively assess the amount of nanoparticles accumulated at the tumor site and regulate the MHT field conditions. To conclude, future perspectives with guidance on how to advance MHT therapy will be provided.
8 July 2016 in Angewandte Chemie International Edition
Here, the synthesis and proof of exploitation of three‐material inorganic heterostructures made of iron oxide‐gold‐copper sulfide (Fe3O4@Au@Cu2−xS) are reported. Starting with Fe3O4‐Au dumbbell heterostructure as seeds, a third Cu2−xS domain is selectively grown on the Au domain. The as‐synthesized trimers are transferred to water by a two‐step ligand exchange procedure exploiting thiol‐polyethylene glycol to coordinate Au and Cu2−xS surfaces and polycatechol–polyethylene glycol to bind the Fe3O4 surface. The saline stable trimers possess multi‐functional properties: the Fe3O4 domain, of appropriate size and crystallinity, guarantees optimal heating losses in magnetic hyperthermia (MHT) under magnetic field conditions of clinical use. These trimers have indeed record values of specific adsorption rate among the inorganic‐heterostructures so far reported. The presence of Au and Cu2−xS domains ensures a large adsorption which falls in the first near‐infrared (NIR) biological window and is here exploited, under laser excitation at 808 nm, to produce photo‐thermal heat alone or in combination with MHT obtained from the Fe3O4 domain. Finally, an intercalation protocol with radioactive 64Cu ions is developed on the Cu2−xS domain, reaching high radiochemical yield and specific activity making the Fe3O4@Au@Cu2−xS trimers suitable as carriers for 64Cu in internal radiotherapy (iRT) and traceable by positron emission tomography (PET).